Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia

NCT02330718 | Unknown

• 1 other identifier: 4-2014-0236
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to elucidate the factors which are associated with the diagnosis and predict prognosis and therapeutic targets by collecting specimens of tissue sample, peripheral blood, and bone marrow aspirates at the time of diagnosis or relapse/refractory in patients with malignant hematologic disorders except acute leukemia. This study is eligible for patients who are diagnosed with malignant hematologic disorders except acute leukemia or who will have diagnostic procedure with suspicion of having hematologic malignancy. Prospective cohort is for patients who are not in treatment for hematologic malignancy. Retrospective cohort is for patients who are diagnosed and in treatment.

Conditions

Malignant Hematologic Disorder

Outcome Measures

Primary Outcomes (1)

• the number of patients with malignant hematologic disorders to examine the new prognostic factors and therapeutic targets

  5 years

Interventions

No intervention OTHER

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed or relapsed malignant hematologic disorders except acute leukemia

You may qualify if:

• The patients with malignant hematologic disorders except acute leukemia who are diagnosed pathologically according to the revised 2008 WHO classification of tumours of haematopoietic and lymphoid tissue or who will have diagnostic procedure with suspicion of having hematologic malignancy.
• Any gender and age ≥ 19 years
• Written informed consent
• Diagnosed after 2005-01-01 in retrospective cohort group.

You may not qualify if:

• Patients who cannot understand or disagree the informed consent
• Patients who diagnosed with acute leukemia

Sponsors & Collaborators

• Yonsei University: lead

Study Sites (1)

Severance Hospital

Seoul, 120-752, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

peripheral blood and bone marrow aspirates have been collected and stored for the study

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2014
• First Posted: January 5, 2015
• Study Start: May 1, 2014
• Primary Completion: December 1, 2019
• Study Completion: April 1, 2020
• Last Updated: February 22, 2019

Record last verified: 2019-02

Locations

KR (1)